Enliven Therapeutics (NASDAQ:ELVN) Releases Earnings Results, Misses Estimates By $0.10 EPS

Enliven Therapeutics (NASDAQ:ELVN) posted its quarterly earnings results on Wednesday. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10), FiscalAI reports.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock traded up $0.21 on Friday, reaching $60.48. The stock had a trading volume of 265,495 shares, compared to its average volume of 1,282,728. The business’s 50-day moving average price is $48.21 and its two-hundred day moving average price is $39.53. Enliven Therapeutics has a fifty-two week low of $14.78 and a fifty-two week high of $62.32. The stock has a market cap of $3.68 billion, a P/E ratio of -35.90 and a beta of 0.27.

Analysts Set New Price Targets

ELVN has been the topic of a number of recent research reports. JonesTrading boosted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Guggenheim cut their price target on Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Thursday. Mizuho lifted their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. Finally, The Goldman Sachs Group increased their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $72.67.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Friday, July 17th. The shares were sold at an average price of $52.64, for a total transaction of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. The trade was a 11.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director owned 87,373 shares of the company’s stock, valued at $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 190,831 shares of company stock worth $10,991,723. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the business. Vestal Point Capital LP increased its position in Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the period. TCG Crossover Management LLC bought a new stake in Enliven Therapeutics in the 2nd quarter valued at $9,990,000. Duquesne Family Office LLC boosted its holdings in Enliven Therapeutics by 104.6% in the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after purchasing an additional 484,405 shares during the period. Marshall Wace LLP grew its position in Enliven Therapeutics by 2,886.9% in the 2nd quarter. Marshall Wace LLP now owns 333,333 shares of the company’s stock worth $6,687,000 after purchasing an additional 322,173 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Enliven Therapeutics by 148.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 398,893 shares of the company’s stock worth $6,143,000 after purchasing an additional 238,434 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.